To explore the material basis and molecular mechanism of Danshen(Salviae Miltiorrhizae Radix et Rhizoma) combined with Honghua(Carthami Flos) against coronary heart disease(CHD) based on network pharmacology.Methods:The active compounds of Danshen-Honghua(DS-HH) were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and screened out according to oral bioavailability and drug-likeness.The targets of chemical compounds were predicted by PubChem and PharmMapper,and related targets of CHD were retrieved from DisGeNET.The common targets of CHD and DS-HH were obtained by Venny 2.1 and imported into STRING 10.5 for protein-protein interaction(PPI) network analysis.The drug-component-target-disease network was constructed by Cytoscape 3.7.1.Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analyses were performed by DAVID 6.8.Results:Thirteen key chemical compounds and 10 key targets were screened out from DS-HH.A total of 292 biological processes(BP),25 cellular components(CC),and 62 molecular functions(MF) were obtained by GO analysis.KEGG analysis yielded 115 enrichment pathways.Quercetin,luteolin,kaempferol,tanshinone Ⅱa,and baicalin might be the core compounds of DS-HH against CHD.IL6,AKT1,VEGFA,CXCL8,PTGS2,IL1B,NOS3,CCL2,and MMP9 might be the key targets.The fluid shear stress and atherosclerosis pathway,HIF-1 signaling pathway,IL-17 signaling pathway,TNF signaling pathway,and relaxin signaling pathway might be the core signaling pathways.Conclusion:DS-HH played a role in the treatment of CHD by regulating the process of coronary atherosclerosis,reducing vascular inflammation,dilating coronary arteries,preventing thrombosis,and relieving myocardial ischemia and hypoxia injury.